NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

CXC趋化素受体1 (CDw128a、高亲和性白细胞介素8受体A、IL-8受体1、CD181、CXCR1) :开发平台分析

C-X-C Chemokine Receptor Type 1 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品编码 361649
出版日期 内容资讯 英文 59 Pages
订单完成后即时交付
价格
CXC趋化素受体1 (CDw128a、高亲和性白细胞介素8受体A、IL-8受体1、CD181、CXCR1) :开发平台分析 C-X-C Chemokine Receptor Type 1 - Pipeline Review, H2 2019
出版日期: 2019年12月27日内容资讯: 英文 59 Pages
简介

本报告提供CXC趋化素受体1 (CDw128a,高亲和性白细胞介素8受体A,IL-8受体1,CD181,CXCR1)的开发情形调查分析,开发中产品的概要,临床实验的各阶段的产品概要,主要企业简介,药物简介,开发中产品的最新趋势,最新消息和新闻稿等系统性资讯。

目录

简介

概要

治疗药的开发

  • 开发中的产品:各开发阶段
  • 开发中的产品:各治疗领域
  • 开发中的产品:各适应症

开发中产品的概要

  • 后期阶段的产品
  • 初期阶段的产品

开发中的产品:各企业

各开发中的产品:各大学/研究机关

治疗药的评估

  • 单剂/联合治疗
  • 各作用机制
  • 各给药途径
  • 各分子类型

开发治疗药的企业

  • Dompe Farmaceutici S.p.A.
  • Syntrix Biosystems, Inc.

药物简介

暂停的计划

开发中止的产品

最新消息和新闻稿

附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC2091TDB

Summary

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report C-X-C Chemokine Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - C-X-C Chemokine Receptor Type 1 is a receptor for interleukin 8 (IL8). It binds to IL8 with high affinity, and transduces the signal through a G-protein-activated second messenger system. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. This receptor binds to IL-8 with a high affinity and to MGSA (GRO) with a low affinity. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Respiratory, Central Nervous System, Dermatology and Metabolic Disorders which include indications Autoimmune Disorders, Bronchopulmonary Dysplasia, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammation, Inflammatory Pain, Liver Transplant Rejection, Lung Cancer, Melanoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Islet Transplant Rejection, Post-Operative Pain, Pulmonary Inflammation, Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes) and Uveal Melanoma.

Furthermore, this report also reviews key players involved in C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)
  • The report reviews C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Overview
  • C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Companies Involved in Therapeutics Development
  • Dompe Farmaceutici SpA
  • Eli Lilly and Co
  • Merck & Co Inc
  • Rise Biopharmaceutical Ltd
  • Syntrix Biosystems Inc
  • Vaccibody AS
  • C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Drug Profiles
  • DF-2755A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ladarixin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-3041658 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • navarixin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PAC-G31P - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein to Antagonize CXCR1 and CXCR2 for Pancreatic Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • reparixin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SX-517 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SX-576 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SX-682 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine for Melanoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Dormant Products
  • C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Discontinued Products
  • C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 04, 2019: Duke Health: New, non-hormonal target identified for advanced prostate cancer
  • Jun 20, 2019: Syntrix Pharmaceuticals announces dosing of first patient in phase 1/2 clinical trial of SX-682 in Combination with KEYTRUDA (pembrolizumab) in metastatic melanoma
  • Apr 08, 2019: Researchers report SX-682 could enhance multiple forms of T cell-based immunotherapies in solid tumors
  • Mar 26, 2019: New study points to SX-682 as strategy to boost immunotherapy effectiveness in advanced colorectal cancer
  • Feb 04, 2019: Syntrix wins $3.4M NIH grant to conduct phase 1/2 trial of SX-682 in Myelodysplastic Syndrome
  • Dec 10, 2015: Research presented at the San Antonio Breast Cancer Symposium intended to strike at the heart of cancer stem cells
  • Oct 05, 2015: Study Available at Fox Chase Cancer Center Evaluates the Use of Reparixin in Combination with Paclitaxel for the Treatment of Metastatic Triple Negative Breast Cancer
  • Oct 01, 2014: Dompe commitment in oncology against cancer stem cells
  • Sep 25, 2013: Pharmaceutical company Dompe launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation
  • Jul 10, 2013: Dompe announces innovative treatment in the fight against type 1 diabetes: pancreatic islet cell transplantation, a hope that has already come true
  • Dec 06, 2012: Dompe Announces Presentation Of Reparixin Clinical Trial Data In Metastatic Breast Cancer At 34th CTRC-AACR San Antonio Breast Cancer Symposium
  • Oct 23, 2012: Dompe Announces Enrollment Of First Patient In Phase III Trial On Reparixin
  • Oct 24, 2011: Dompe Announces Presentation Of Phase II Clinical Data Of Reparixin For Improvement Of Efficacy of Pancreatic Islet Transplantation At 2011 CTS-IXA Congress
  • Oct 13, 2011: Dompe's Reparixin Receives EMA Orphan Drug Designation For Prevention Of Graft Rejection In Pancreatic Islet Transplantation
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Dompe Farmaceutici SpA, H2 2019
  • Pipeline by Eli Lilly and Co, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Rise Biopharmaceutical Ltd, H2 2019
  • Pipeline by Syntrix Biosystems Inc, H2 2019
  • Pipeline by Vaccibody AS, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019